Actelion Pharmaceuticals Canada

Actelion Pharmaceuticals Canada



Actelion Pharmaceuticals Canada Inc. was founded in 2001 and is located in Laval, Quebec. Actelion employs 36 individuals.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Actelion Canada is involved in phase III clinical research and the commercialization of products in Pulmonary Arterial Hypertension (Tracleer, Opsumit, Uptravi and Caripul).  Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV.  In Canada, Actelion also has treatments approved for  Type 1 Gaucher disease (Zavesca), Niemann-Pick type C disease (Zavesca) and Chronic Hand Eczema (Toctino).

Actelion Canada has assembled a group of talented and dedicated individuals passionate about making a difference.